Goodwin represented Base Therapeutics on the matter. Base Therapeutics announced the out-licensing of its proprietary base editing technology on a non-exclusive basis to a leading international biopharmaceutical…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
